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Abstract
Background: Improper chronic proton pump inhibitor (PPI) use has 
risen significantly in the last few decades. In our gastroenterology 
trainees’ clinics, we aimed to optimize PPI usage.
Methods: We collected baseline data on patients’ PPI use for 8 
weeks. Based on gastroenterology society guidelines, we determined 
conditions for appropriate PPI use. If the indication could not be 
determined, it was categorized as “unknown”. Generated from the 
three most frequent causes for inappropriate PPI use, interventions 
were developed to correct each issue. Following a brief educational 
session, trainees implemented these interventions over a subsequent 
8-week interval.
Results: During our pre-intervention period, trainees evaluated 263 
patients who were prescribed a PPI. In 49% of the cases, the use of 
PPI was deemed inappropriate. The most common reasons were: 
gastroesophageal reflux disease (GERD) which was never titrated to 
the lowest effective dose, twice daily dosing for Barrett’s esophagus 
(BE) chemoprevention and unknown indication. During our inter-
vention period, trainees evaluated 145 patients prescribed a PPI for 
GERD with well-controlled symptoms in 101 cases. PPI had not been 
titrated to lowest effective dose in 37 cases prompting intervention 
which was successful in 23 cases. PPI indication was unknown in 
17 cases prompting a message to the prescribing provider to review 
appropriateness. Two cases of BE chemoprevention with twice daily 
dosing were appropriately reduced to daily dosing. Ultimately, after 
intervention, PPI use was deemed appropriate after intervention in 
172 (77%) cases.
Conclusions: Improper chronic PPI use was significant. Focusing in-
tervention efforts on PPI use for GERD, BE and unknown indications 
substantially increased appropriateness of PPI use.
Keywords: Stewardship; Prescribing initiatives; Appropriate use; 
Proton pump inhibitors
Introduction
Proton pump inhibitors (PPIs) have been widely prescribed 
and heavily marketed since their introduction in 1989. Excel-
lent short-term efficacy of PPI therapy has been demonstrated 
for specific indications including erosive esophagitis and up-
per gastrointestinal (GI) bleeding due to peptic ulcer disease 
(PUD) [1-3]. Chronic use of PPI therapy is frequently pre-
scribed for chemoprevention of acid-related complications and 
ulcer disease in addition to maintenance therapy for chronic 
conditions including dyspepsia, eosinophilic esophagitis (EoE) 
and gastroesophageal reflux disease (GERD) [4, 5].
However, improper chronic PPI use has risen significant-
ly in the last few decades with PPI misuse reported to range 
from 20% to 80% across both hospital and ambulatory set-
tings [6, 7]. Though rates were lower among academic institu-
tions compared to non-academic, they are still at nearly 50% 
[8]. The most frequently cited reasons for PPI overuse include 
the prevention of peptic ulcers in patients without risk factors, 
stress ulcer prophylaxis in non-intensive care units and the 
overtreatment of functional dyspepsia [9, 10].
PPIs have favorable safety profiles in short-term use with 
most common side effects of headache and diarrhea occurring 
in 2-5% of patients. However, the safety of chronic PPI use has 
been challenged recently in highly publicized reports noting 
associations with chronic kidney disease, dementia and bone 
fractures [11-14]. Overall usage of PPI decreased in 2012 for 
the first time since its introduction in 1989 which may be relat-
ed to the rising fears of potential PPI-related side effects [15].
PPI stewardship programs are being developed in which 
active PPI prescription appropriateness is reassessed. Phar-
macy-driven initiatives have focused on deprescribing inap-
propriate PPI treatments in long-term care facilities’ patients 
and in geriatric patients at risk of polypharmacy [16-18]. We 
recognize that our institution’s providers and our patients are 
not immune to this issue. Thus, we developed a quality im-
provement to optimize PPI use at our institution. The purpose 
of this quality improvement project is to optimize our patients’ 
usage of PPIs and thus decrease their risk for potential adverse 
events from inappropriate chronic PPI use. We aimed to en-
sure that our patients were prescribed PPIs for an appropriate 
indication, especially in cases of chronic (> 12 weeks) PPI use.
Materials and Methods
The quality improvement study was developed and executed 
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by the trainees in our gastroenterology and hepatology fellow-
ship program within the context of our trainee continuity clin-
ics at the affiliated county hospital and veterans affairs (VA) 
medical center. The project leaders were the authors of this 
manuscript: one GI fellow team leader at each of the two clin-
ics, the chief fellow and the GI fellowship program director. 
All trainees who participated in the initiative were gastroen-
terology fellows. As the project was designed as a quality im-
provement initiative, this study was exempt from institutional 
review board (IRB) review. This study was conducted in com-
pliance with the ethical standards of the responsible institution.
To first determine the extent of inappropriate PPI use in 
the trainee continuity clinics and evaluate the most frequent 
causes, baseline data were collected during an 8-week time pe-
riod. During this pre-intervention phase, only data pertaining 
to patients’ medications prior to the time of the clinic visit were 
captured to avoid bias. Any changes made during the clinic 
visit were not reflected in this initial data collection. During 
each encounter, the use of PPI was documented (including 
drug name, dose, frequency, duration and indication) in a des-
ignated location in the clinical note. The use of other antacids, 
including H2 blockers, was not collected during this study as 
this was not the focus of this quality initiative. Basic demo-
graphic information, including age and sex, was collected 
from each patient. Based upon approved indications for PPIs 
published in the gastroenterology society guidelines, indica-
tions were noted as predetermined categories: GERD, dyspep-
sia, PUD, Barrett’s esophagitis (BE), EoE and Helicobacter 
pylori [19-26]. For each patient, all applicable indications 
were captured. If the apparent indication for PPI use was not 
consistent with any of the above, it was categorized as “other”. 
If the indication was neither known by the patient nor apparent 
upon review of the two most recent primary care physicians’ 
and GI physicians’ notes in the medical record, it was desig-
nated as “unknown”.
At the end of this 8-week pre-intervention phase, a retro-
spective examination of each trainee’s patient encounters was 
performed by another trainee to determine whether PPI use 
had been appropriate or inappropriate in each case. Appropri-
ateness was assessed by the aid of an algorithmic flowchart 
created by the project leaders. The flowchart included guide-
line-based recommendation statements describing appropriate 
PPI use for the various upper GI conditions noted above. The 
algorithmic flowchart guided trainees by using a series of yes 
or no questions based upon indication for PPI prescription. If 
the medication was prescribed for more than one indication, 
the algorithm guided trainees to follow the pathway for the 
indication with the most lenient PPI prescribing guidelines 
(GERD in the majority of cases). In some cases, additional 
information was abstracted from the medical record to make 
this determination. For example, in patients with PUD due to 
a nonsteroidal anti-inflammatory drug (NSAID) who remained 
on PPI therapy after the initial 8-week treatment period, con-
tinuation was considered appropriate if the patient required 
to remain on the offending NSAID. In patients with GERD, 
history of reflux esophagitis, presence of ongoing symptoms 
and whether previous dose titration had been attempted were 
recorded. In patients with dyspepsia and PUD, prior H. pylori 
testing status was noted as this would affect therapy accept-
ability under guidelines. For all patients with PUD, the ulcer 
etiology was captured (H. pylori, medication-related, hyper-
secretory conditions, idiopathic) as acceptability of continued 
PPI use varies depending on etiology. If PUD was medication-
related, the reviewers determined if the offending medication 
was continued or discontinued after ulcer disease was diag-
nosed. PPI use automatically was deemed inappropriate if the 
indication was either “other” or “unknown”. The most fre-
quent noted indication in the “other” category was use of PPI 
in the setting of esophageal varices with or without a history 
of prior variceal bleeding. Finally, the project leaders compiled 
and analyzed the data.
To achieve the greatest impact, the intervention was di-
rected towards reducing the inappropriate PPI use for the three 
most common conditions associated with PPI misuse as iden-
tified during the pre-intervention phase. The intervention in-
cluded an educational session and a corresponding template 
with a stepwise approach to be utilized when completing clini-
cal documentation. The education session consisted of a brief 
PowerPoint presentation describing the approved indications 
for PPIs with discussion of appropriate and inappropriate use 
[9]. When only prescribed for GERD, the education empha-
sized the importance of titrating PPI to the lowest effective 
dose. The presentation also underscored that only once daily 
dosing is recommended as maintenance PPI therapy for non-
GERD conditions. During the educational session, the provid-
ers were given an algorithm similar to that used in the pre-
intervention phase to illustrate appropriate PPI use and were 
also offered additional guidance to correct misuse for the three 
main indications identified (Fig. 1).
During the 8-week intervention period, the providers com-
pleted the template integrated into the clinical documentation. 
The template noted a series of steps, the first of which was a 
reminder to perform a GI medication reconciliation with the 
patient, especially focusing on PPIs. The indication was again 
noted for each patient with specific reminders in the template 
addressing GERD, BE and unknown indications. If the indica-
tion was discovered to be unknown, a message was sent in the 
electronic medical record to the patient’s primary care physi-
cian to inquire if the drug should be continued. For indications 
of GERD and BE, the template included reminders of the ap-
propriate use of PPI in these settings and prompted providers 
to modify the drug dosing during the visit if appropriate and 
document the changes. For indications other than unknown, 
GERD and BE, any changes to PPI therapy were up the discre-
tion of the provider.
At the conclusion of the 8-week intervention phase, the 
clinical documentation was reviewed by another trainee who 
determined if PPI use had been appropriate in each case. The 
data were again compiled and analyzed by the project leaders.
Results
During the 8-week pre-intervention phase, 566 patients were 
evaluated by 15 trainee providers in the county hospital and 
associated VA gastroenterology clinics. Of those 566 patients, 
263 (46%) patients were prescribed a PPI. Esomeprazole, 
omeprazole and pantoprazole were the prescribed PPIs in 260 
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of the 263 cases. Among those 263 patients, the most common 
indication was GERD (64%), followed by dyspepsia (10%), 
BE chemoprevention (8%) and PUD (5%). The “other” cat-
egory included 13 (5%) patients which included three cases of 
PUD prophylaxis for chronic steroid use, four cases of variceal 
bleeding prophylaxis and four cases of globus sensation or lar-
yngopharyngeal symptoms. After our reviewers assessed PPI 
appropriateness employing the guideline-based algorithm, PPI 
use was found to be inappropriate in 129 patients (49% of pa-
tients prescribed a PPI). The most frequent cause for PPI mis-
use (found in 64 patients (50%) of patients with inappropriate 
PPI use) was PPI taken for an indication of GERD alone which 
was never titrated to lowest effective dose. Of these 64 cases, 
42 patients were on a double dose PPI. The second most com-
mon inappropriate use was an “unknown” indication for the 
drug (14% of patients with inappropriate PPI use). The third 
most common inappropriate use was continued use of double 
dose PPI for BE chemoprevention while patient did not have 
any active GERD symptoms (10% of patients with inappropri-
ate PPI use). Combined, these three categories of inappropri-
ate PPI use accounted for nearly 75% of cases of PPI misuse. 
Table 1 reports all PPI indications and appropriateness of use.
During the 8-week intervention phase, 224 (46%) of 482 
patients seen in our gastroenterology clinics were actively tak-
ing a PPI prior to clinic visit. PPI use was deemed appropriate 
without intervention in 130 (58%) of 224 patients prescribed a 
PPI. A successful intervention was performed in 42 cases, thus 
ultimately increasing our appropriate PPI use to 172 (77%) of 
Figure 1. Algorithm of interventions based on PPI indication. PPI: proton pump inhibitor; GERD: gastroesophageal reflux dis-
ease; BE: Barrett’s esophagus; EoE: eosinophilic esophagitis; PUD: peptic ulcer disease; PCP: primary care provider; GI: gas-
trointestinal.
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224 cases after intervention (Table 2). Details of our focused 
interventions for our three indications of interest are described 
below.
At the time of clinic visit, GERD symptoms were well 
controlled in 101 (70%) of the 145 patients prescribed a PPI 
for GERD. A provider had previously titrated the PPI to the 
lowest effective dose in 64 of the 101 well-controlled patients: 
standard dosing in 61 patients and half dose daily or as needed 
(PRN) dosing in three patients. However, 37 of the 101 (37%) 
patients were on double dose PPI therapy but had not attempt-
ed to titrate down to lowest effective dosing. These cases were 
deemed to be inappropriate PPI use and the providers success-
fully decreased the PPI dose by at least half in 23 (62%) of the 
37 cases. The most common cause cited for failed attempt to 
de-escalate the dose was the patient’s unwillingness to reduce 
the dose due to concerns about increased frequency of uncon-
trolled reflux symptoms.
The indication for PPI therapy was BE chemoprevention 
in 15 (7%) of 224 patients prescribed PPI who were evalu-
ated during the 8-week intervention phase. Two cases of BE 
chemoprevention had been inappropriately maintained on BID 
dosing and this was appropriately reduced to daily dosing. The 
other 13 cases were already appropriately dosed and did not 
require further dosing modification.
The indication of PPI was unknown in 17 (8%) cases after 
discussion with the patient and review of the electronic medi-
cal record (EMR). This finding prompted the provider to send 
a message to the prescribing provider to review appropriate-
ness and this was completed in all 17 cases.
Despite our focused interventions, 52 cases were consid-
ered having inappropriate PPI use at the time of analysis. These 
52 cases included 14 patients who refused the provider’s inter-
vention because of concern about worsening GERD symptoms 
if PPI regimen was adjusted, 24 patients with inappropriate 
PPI use prescribed for an indication that was not specifically 
addressed by the intervention and 14 cases during which the 
provider had to address more urgent issues and could not de-
termine nor discuss PPI appropriateness in the allotted visit 
time.
Discussion
In our study, significant PPI misuse was discovered in a popu-
lation of ambulatory gastroenterology patients seen in trainee 
continuity clinics in VA and county hospital settings. Baseline 
data established that the most common cause of inappropriate 
use was maintenance non-titrated double dose PPI use in pa-
tients with uncomplicated GERD who had achieved control of 
their symptoms. Other leading causes of misuse were double 
dosing of PPI for BE chemoprevention and the absence of an 
apparent indication after review of the EMR and discussion 
with the patient. An intervention was developed to address 
these three most common issues. Intervention included a brief 
educational session and a written template integrated into clin-
ical notes, both centered on an algorithm approach. Inappro-
priate PPI use decreased to 23% after intervention compared 
to 49% at baseline.
Our results are similar to previous studies assessing PPI Ta
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misuse in the outpatient setting, including the high prevalence 
of unknown indication for PPI prescription [7]. One major 
cause for this phenomenon is assumed to be the continuation of 
the medication after a hospitalization. A study of this practice 
reported that two-thirds of discharge summaries indicated that 
the medication should be continued at home; however, no clear 
indication to do so could be identified [27]. Furthermore, in up 
to 70% of the cases, these medications are continued chroni-
cally after discharge by primary care providers (PCPs) [28]. 
These findings highlight the often noted deficiencies in com-
munication between providers during transitions of care. In an 
attempt to mitigate the prevalence of unknown indications for 
PPIs, our intervention focused on thorough medication rec-
onciliation with the patient and a mandate to communicate to 
PCPs or prescribing providers when discovered. Our project 
did not include requesting feedback from the PCPs to deter-
mine if the inappropriate PPI use was appropriately changed or 
stopped. This is a limitation which could be pursued in future 
iterations of this quality improvement project.
Our study found GERD to be the most common diagnosis 
associated with chronic PPI overuse, though the initial indi-
cation may have been appropriate. The studies which estab-
lished PPIs as the preferred agents for treatment of GERD 
focused on healing of erosive esophagitis as their primary 
endpoint. However, it has since been realized that up to 70% 
of GERD patients can be categorized as having non-erosive 
reflux disease (NERD) [29], thus the goal of therapy is symp-
tom control alone. The American Gastroenterology Associa-
tion guideline on the management of GERD recommends to 
decrease therapy to the lowest effective dose; however, this 
is infrequently done [21, 22]. PPIs are commonly continued, 
often at high doses, long term without reassessment or dose 
reduction [7]. Attempts to step down therapy have been iden-
tified in only 20-33% of patients with uncomplicated GERD 
alone [30].
Excessive dose of PPI for BE chemoprevention was a sig-
nificant cause of inappropriate PPI prescription in our study. 
However, this is not a commonly cited issue reported in the lit-
erature. In fact, all of the cases of inappropriate PPI use for BE 
chemoprevention in our study were noted at the VA hospital. 
This discrepancy was likely due to the increased prevalence of 
BE in our VA patient cohort compared to the county hospital 
cohort. Of note, the aspect trial was published after the start 
of our quality improvement project [31]. Using a combined 
endpoint of time to all-cause mortality, esophageal adenocarci-
noma, or high-grade dysplasia, this study supported the use of 
high dose twice daily PPI over single dose daily PPI. As these 
findings have not been formally integrated into recommen-
dations in the gastroenterology society published guidelines, 
double dose PPI was still considered inappropriate for the pur-
poses of our study. Over-prescription of PPI for dyspepsia was 
not prevalent in our study, though it is one of the most com-
monly cited inappropriate indications in the literature. Howev-
er, dyspepsia was the second most common indication for PPI 
use noted in our study’s baseline data collection. Therefore, the 
educational interventions described above in relation to GERD 
can be similarly applied to dyspepsia.
The strengths of our study stem from the intervention it-
self. Though our study was implemented by trainees at an aca-
demic center, the algorithm applied is user-friendly and widely 
applicable in many practice settings, including primary care, 
as it is based upon gastroenterology society guidelines. The 
tool could also be expanded to pharmacists, as has been done 
in other studies, to help alert providers to possible inappropri-
ate PPI use. One limitation of our study is generalizability, as 
it was conducted at an academic center in the trainees’ general 
gastroenterology clinics. Our intervention focused on educa-
tion of trainees to step down therapy when appropriate and 
appeared to have significant success. Given that our study was 
conducted over a relatively short time-frame by clinicians who 
arguably had a vested interest in improving PPI misuse, this 
could be viewed as another limitation. In a review of 21 stud-
ies aiming to discontinue inappropriate PPI use, only six noted 
effective interventions, one of which was based on provider 
education [30]. Three of the other studies based on education 
were ineffective. The authors concluded that clinician enthusi-
asm was likely a significant factor in potential success of such 
interventions.
Future areas of improvement for this quality project in-
clude performing another Plan-Do-Act cycle with a modified 
intervention to achieve the goal of 100% appropriate PPI use 
for these three specific conditions and eventually additional 
conditions associated with misuse. Another area for further 
study would be to investigate the durability of the intervention 
to determine if the improvement in PPI misuse was maintained 
after the conclusion of the project. Other future directions in-
clude disseminating this algorithmic approach intervention to 
other GI training programs and also to internal medicine and 
family medicine training programs to improve appropriate PPI 
use for primary care physicians.
In conclusion, our study highlights that failure to step 
down therapy in GERD is a significant and primary cause of 
inappropriate chronic PPI use. With an education-based inter-
vention using an algorithm adapted from multiple GI society 
guidelines, PPI misuse can be significantly reduced in GERD 
and other conditions.
Table 2.  PPI Appropriateness of Use During the 8-Week Intervention Period
Indication Total number of patients on PPI due to indication
Number of patients with inappro-
priate use prior to intervention
Number of patients successfully con-
verted to appropriate use by intervention
Well-controlled GERD 101 37 23
BE chemoprevention 15 2 2
Unknown 17 17 17
PPI: proton pump inhibitor; GERD: gastroesophageal reflux disease; BE: Barrett’s esophagus.
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